Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lincoln PharmaceuticalsNSE:LINCOLN +4.50%84 5-Year Yield-on-Cost % is 0.30 as of Aug. 14, 2026, which is 36% below its 10-year median of 0.47. GuruFocus rates NSE:LINCOLN with a GF Score™ of 84/100 and a GF Value™ of ₹727.62 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 511 Drug Manufacturers companies, Lincoln Pharmaceuticals ranks worse than 89.43% on this metric.
The historical rank and industry rank for Lincoln Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:LINCOLN'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.19 Med: 0.47 Max: 2.47
Current: 0.3
During the past 13 years, Lincoln Pharmaceuticals's highest Yield on Cost was 2.47. The lowest was 0.19. And the median was 0.47.
NSE:LINCOLN's 5-Year Yield-on-Cost % is ranked worse than 89.43% of 511
companies
in the Drug Manufacturers industry
Industry Median: 2.3
vs NSE:LINCOLN: 0.30
Lincoln Pharmaceuticals (NSE:LINCOLN) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Lincoln Pharmaceuticals 5-Year Yield-on-Cost % Related Terms
NSE:LINCOLN vs ZTS: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lincoln Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lincoln Pharmaceuticals 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lincoln Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Lincoln Pharmaceuticals's 5-Year Yield-on-Cost % falls into.
Lincoln Pharmaceuticals 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Lincoln Pharmaceuticals (NSE:LINCOLN) has a 5-Year Yield-on-Cost % of 0.30 as of Aug. 14, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Lincoln Pharmaceuticals and its competitors. This is 36% below median its historical median of 0.47. Over the past decade, Lincoln Pharmaceuticals' 5-Year Yield-on-Cost % has ranged from 0.19 to 2.47. According to the industry distribution chart, Lincoln Pharmaceuticals ranks #457 out of 511 companies in the Drug Manufacturers industry, placing it in the top 89.4%.
Is Lincoln Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Lincoln Pharmaceuticals' current 5-Year Yield-on-Cost % of 0.30 is 36% below median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 2.47. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.30. Lincoln Pharmaceuticals' value of 0.30 is 87% below this industry median. Based on the distribution chart, Lincoln Pharmaceuticals ranks #457 out of 511 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Lincoln Pharmaceuticals has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lincoln Pharmaceuticals' 5-Year Yield-on-Cost % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Lincoln Pharmaceuticals ranks #457 out of 511 companies for 5-Year Yield-on-Cost %. This places Lincoln Pharmaceuticals in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.30. Lincoln Pharmaceuticals' value of 0.30 is 87% below this benchmark. Historically, Lincoln Pharmaceuticals' own 5-Year Yield-on-Cost % has ranged from 0.19 to 2.47 over the past decade. While the company's 10-year median is 0.47 vs. the industry median of 2.30, Lincoln Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.30, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lincoln Pharmaceuticals's current 5-Year Yield-on-Cost % of 0.30 is 87% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Lincoln Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lincoln Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.30, which is 36% below median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lincoln Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals (NSE:LINCOLN) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹727.62, compared to a current price of ₹619.50 — trading 14.9% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.30, which is 36% below median its 10-year median of 0.47 and 87% below the Drug Manufacturers industry median of 2.30. Lincoln Pharmaceuticals' overall GF Score™ is 84/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Lincoln Pharmaceuticals (NSE:LINCOLN), the current 5-Year Yield-on-Cost % is 0.30 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lincoln Pharmaceuticals (NSE:LINCOLN) Overvalued in 2026?
Based on GuruFocus' analysis, Lincoln Pharmaceuticals stock appears to be undervalued.
The current stock price of ₹619.50 is trading 14.9% below its estimated GF Value™ of ₹727.62.
GuruFocus considers Lincoln Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for NSE:LINCOLN:
5-Year Yield-on-Cost %: 0.30 (36% below median its 10-year median of 0.47)
GF Value™: ₹727.62 vs. price of ₹619.50 (14.9% below fair value)
Industry Position: 87% below the Drug Manufacturers median (#457 of 511)
No single metric tells the full story. See the NSE:LINCOLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.
84GF Score
Get the complete analysis for NSE:LINCOLN
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:LINCOLN has been successfully added to your 
